fbpx

Company

WHO WE ARE

PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas.  The location of our operations provides us with many potential strategic advantages, including proximity to world-class cancer institutions and researchers and the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas, or CPRIT.  Since being founded in 2008, CPRIT has awarded almost $2.5 billion in funds toward more than 1,500 grants for cancer prevention and academic/product development research.

We have two lead drug product candidates in our pipeline, RNL™ and DocePLUS™, being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.  This diverse and experienced team is using our proprietary and versatile nanotechnology platform to reformulate and deliver U.S. FDA-approved chemotherapeutics and widely-used radiotherapeutics in Europe to provide meaningful benefits to patients and healthcare providers.  The platform also serves as the foundation and affords us the opportunity in the future to develop additional drugs for rare cancers.

OUR MISSION

We believe in the critical importance of discovering, developing, and delivering complex and innovative treatments for patients battling rare cancers.

OUR VISION

We envision medicines that will drastically enhance clinical and economic outcomes for patients and providers and forever change the future of human health worldwide.

OUR VALUES

Our company values guide our beliefs, behaviors, and interactions.  

Our goal is to live out these values everyday, everywhere, and with everyone.

Accountability

Reliability, responsibility, and taking ownership of our work.

Agility

Ability to quickly respond and adapt to internal and external changes without losing our momentum.

Communication

Welcome transparency and direct feedback from colleagues, partners, providers, and patients alike.

Innovation

Possess ongoing curiosity and courage to boldly experiment and discover.

Integrity

Consistently remain ethical and commit to always doing the right thing, no matter what.

Patient-Centric

Keep our passion for the patient forever at the forefront of all we do.

U

Quality

Promise to deliver exceptional results and continually strive to enhance our standards.

Performance

Focus on achievement, taking smart risks, and delivering exceptional results.

w

Respect

Treat everyone we come in contact with dignity and kindness.

Teamwork

Cultivate a culture that encourages collaboration and welcomes different perspectives.

OUR MODEL

MANAGEMENT TEAM

Marc Hedrick, MD

President and CEO

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.  Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

Email

Andrew Sims

Vice President and Chief Financial Officer

Andrew Sims is Vice President and Chief Financial Officer at PLUS THERAPEUTICS, Inc.  Mr. Sims arrives at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price. Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.

Email

Russ Havranek

Vice President - Corporate Strategy and New Product Planning

Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at PLUS THERAPEUTICS, Inc.  He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics Inc.  Mr. Havranek has 24 years of marketing, general management, and product development experience with major life science companies including Johnson & Johnson, Guidant Corporation (now Abbott), Genentech Inc. (now Roche), and Volcano Corporation (now Philips).  Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.

Email

Cheri Rice

Vice President - Product Development

Cheri Rice is the Vice President of Product Development at PLUS THERAPEUTICS, Inc.  She previously served in the same role at Cytori Therapeutics Inc.  Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Plus Therapeutics. Ms. Rice has her bachelor’s degree in Mechanical Engineering from San Diego State University.

Email

Gregory Stein, MD

Senior Vice President - Clinical Development

Dr. Gregory Stein is Senior Vice President of Clinical Development at PLUS THERAPEUTICS, Inc. Prior to joining PLUS, Dr. Stein was a founder and executive of a number of healthcare and biotechnology companies. Most recently he co-founded and served as Chief Executive Officer at Curtana Pharmaceuticals, which develops drugs for the treatment of glioblastoma and other brain cancers. Curtana was awarded funding from the Cancer Prevention and Research Institute of Texas. Prior to Curtana, Dr. Stein was also a founder and served as the Vice President, Operations and Medical Affairs at Sova Pharmaceuticals, Inc., a venture-backed company that developed therapies for sleep-related breathing disorders and neuropathic pain. In addition, Dr. Stein has held senior positions at Genoptix, Opus Pharmaceuticals and Uzima Bioscience.

Dr. Stein was formerly a board certified Emergency Medicine Physician and previously practiced in Chicago serving as the Assistant Medical Director of the department and Associate Emergency Medical Services Director for the regional EMS system.

Dr. Stein is a graduate of the accelerated program at the Ohio State University School of Medicine and completed his residency at the University of Illinois Affiliated Hospitals in Chicago. In addition, Dr. Stein has a MBA from The Rady School of Management at UC San Diego.

Email

BOARD OF DIRECTORS

Richard Hawkins

Chairman

Richard J. Hawkins joined us as Director in December 2007 and was appointed to serve as Chairman in January 2018. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and CEO from 2004 until October 2009. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.

Marc Hedrick, MD

President and CEO

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.  Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

Email

An van Es-Johansson, MD

Director

An van Es-Johansson joined our Board in January 2020. Dr. van Es-Johansson currently serves as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance.  From 2005-2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Swedish Orphan Biovitrum AB (Sobi), an international specialty biopharmaceutical company focused on rare diseases.  Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum.  She currently serves on the Board of Directors at BioInvent International AB, Medivir AB, Agendia Inc., and Savara Inc.  Dr. van Es-Johansson received a M.D. from Erasmus University in Rotterdam, The Netherlands.

Greg Petersen

Director

Greg Petersen has served on our Board since February 2020. Mr. Petersen is an accomplished Executive and Board member with more than 25 years of strategy, operations, finance and compliance leadership experience. His 10 years of Board of Directors experience includes his current roles as Compensation Committee Chair and Audit Committee member of PROS Holdings and as Audit Committee Chair of Mohawk Group Holdings. Mr. Petersen has served as Executive Vice Chairman of Diligent Corporation and as Chief Financial Officer of Lombardi Software and Activant Solutions (now part of Epicor). He has also held executive positions at American Airlines and other corporations. Mr. Petersen has a BA from Boston College and an MBA from Duke University’s Fuqua School of Business.

Robert Lenk, PhD

Director

Robert Lenk joined our Board in March 2020. Dr. Lenk has over 35 years as pharmaceutical executive with deep expertise in nanoparticle drug development and drug formulation. He is currently President of Lenk Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has been Chief Scientific Officer of MediVector, Inc., President of the NanoWorks division of Luna Innovations, Inc., President & CEO of Therapeutics 2000, Inc. and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Lenk was also Cofounder of The Liposome Co. and a Staff Fellow of the National Institute of Child Health and Human Development. He has a PhD and BS from the Massachusetts Institute of Technology and resides in Danville, Virginia.

Howard Clowes

Director

Howard Clowes joined our Board in March 2020. A retired partner after nearly four decades at DLA Piper, a leading law firm, Mr. Clowes has served in leadership positions in the firm’s Corporate and Securities Practice, advising public and private companies on securities law, financing, Mergers and Acquisition and general corporate matters. At the law firm of Gray Cary Ware & Freidenrich LLP, which was acquired by DLA Piper, he served as a partner in the Corporate Group, member of the Executive Committee and managing partner of the Transactions Group. Mr. Clowes has a J.D. from the University of California, Berkeley (where he now serves as a Lecturer), and a BA from the University of California, Santa Barbara. A resident of the Bay Area, Mr. Clowes served as President, Board Member and Chair of the Strategic Planning and Search Committee of the Law Foundation of Silicon Valley.

CLINICAL ADVISORY BOARD

Manish Aghi, MD PhD

Professor, Neurological Surgery, at the Weill Institute for Neurosciences at the University of California, San Francisco.

Dr. Manish Aghi is a neurosurgeon, scientist and current faculty member in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. He completed his MD-PhD Program through the Medical Scientist Training Program at Harvard Medical School, followed by neurological surgery residency and postdoctoral training at Massachusetts General Hospital. Dr. Aghi serves as principal investigator on multiple industry sponsored and investigator-initiated Phase 1-2 clinical trials comparing immunotherapy versus anti-angiogenic therapy of recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy to recurrent glioblastoma.

Nicholas Butowski, MD

Professor, Neurological Surgery and Director, Translational Research, Neuro-Oncology at the Weill Institute for Neurosciences at the University of California, San Francisco.

Dr. Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. Dr. Butowski earned his medical degree at the University of Illinois at Chicago and completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

Russell Lonser, MD

Professor and Chair, Department of Neurological Surgery at The Ohio State University Wexner Medical Center.

Dr. Lonser is a professor and chair of the Department of Neurological Surgery at The Ohio State University Wexner Medical Center, and currently holds the Dardinger Family Chair in Neurosurgical Oncology. Previously, he was chief of the Surgical Neurology Branch at the National Institutes of Health. Dr. Lonser specializes in the resection of brain, spinal cord, pituitary and brainstem tumors. He is a director on the American Board of Neurological Surgeons, and was the head of the research subcommittee in Head, Neck and Spine Injury Committee for the National Football League. Dr. Lonser has served on the editorial boards of NEUROSURGERY, World Neurosurgery, Journal of Neurosurgery, PLoS One and Science Reports.

Alireza Mohammadi, MD

Neurosurgeon at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Mohammadi is a board-certified neurosurgeon who specializes in neurosurgical oncology including surgery and laser ablation of brain tumors as well as radiosurgery for brain and spine. He is currently practicing at Neurosurgery Department and the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic. Since 2014, Dr. Mohammadi has also served as an assistant professor in Neurological Surgery at the Cleveland Clinic Lerner College of Medicine. Dr. Mohammadi earned his medical degree from Tehran University School of Medicine in Tehran, Iran. After completing his residency in neurosurgery at Shohada Hospital, he went on to complete his fellowship in neuro-oncology surgery and his fellowships in radiosurgery at the Cleveland Clinic.

Michael Vogelbaum, MD PhD

Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center.

Dr. Vogelbaum is an internationally known leader in neurosurgical oncology and distinguished investigator in laboratory research, translational and clinical trials in gliomas. He is currently Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Vogelbaum is also the inventor of patented medical devices for delivering therapeutics directly to the brain and brain tumors, with the first of these devices having received U.S. Food and Drug Administration clearance. After completing his M.D. and Ph.D. (Biomedical Engineering) at the University of Virginia, Dr. Vogelbaum completed his residency in neurological surgery at Barnes-Jewish Hospital in St. Louis, Mo.

SCIENTIFIC ADVISORY BOARD

Andrew Brenner, MD PhD

Mays Cancer Center at the UT Health San Antonio

Dr. Brenner is a medical oncologist and tumor biologist with a focus in drug development for the management of primary brain tumors and breast neoplasms. His interests are in developing novel therapeutics for the treatment of malignancy with a focus on overcoming resistance to conventional therapeutics. This experience includes navigation of regulatory processes including IND enabling studies, authoring study protocols, coordinating multicenter studies, as well as acting as principal investigator of 14 industry and investigator-initiated Phase 1 trials since 2008. Dr. Brenner earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center – Science Park. He received his medical degree from the Texas Tech University Health Science Center and completed a residency in internal medicine at Scott and White Hospital in Lubbock, Texas. He completed his fellowship in hematology and medical oncology at the UT Health San Antonio.

John McKew, PhD

Adjunct Professor at the Boston University School of Medicine

Dr. McKew has 27 years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. He is currently Chief Operating Officer of Lumos Pharma. Prior to Lumos Pharma, Dr. McKew was Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. He has also served as Acting Scientific Director for the National Center for Advancing Translational Science (NCATS) intramural group, a part of the National Institute of Health (NIH). At NCATS, his lab’s work on rare diseases and public/private partnerships led to the collaborative advancement of several therapeutic candidates currently being commercialized by pharmaceutical companies. Dr. McKew is also an Adjunct Professor at the Boston University School of Medicine and has previously served as the Chair Elect, Chair and Immediate Past Chair of the American Chemical Society’s Northeastern section. He has over 70 peer-reviewed publications and granted patents. Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry, completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.

Vladimir P. Torchilin , PhD DSc

University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston

Dr. Torchilin is a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He obtained a M.S. in Chemistry as well as a Ph.D. and D.Sc. in Polymer Chemistry and Chemistry of Physiologically Active Compounds from Moscow University. In 1991, Dr. Torchilin joined MGH/Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin has been with Northeastern University, including as the Chair of the Department of Pharmaceutical Sciences from 1998-2008. His research interests include liposomes, lipid-core micelles, biomedical polymers, drug delivery and targeting, pharmaceutical nanocarriers, experimental cancer immunology. He has published more than 400 original papers, more than 150 reviews and book chapters, and holds more than 40 patents. He has also wrote and edited 10 books, including Immobilized Enzymes in Medicine, The Handbook on Targeted Delivery of Imaging Agents, Liposomes: A Practical Approach, Nanoparticulates as Pharmaceutical Carriers, Multifunctional Pharmaceutical Nanocarriers, Biomedical Aspects of Drug Targeting, Delivery of Protein and Peptide Drugs in Cancer.